本项目的开展是依托于国家自然基金面上项目：《基于BAFF/MyD88/NIK 的非经典型NF-κB 信号通路调控淋巴瘤对BTK 抑制剂ibrutinib 的疗效及其机制研究》（项目负责人：李志铭）。QIANG PAN HAMMARSTRÖM 教授与李志铭教授均毕业于中山医科大学，且目前潘嫱教授受聘为中山大学肿瘤防治中心客座教授，相同的教育背景可使今后的合作交流更加融洽，不同的工作经历可相互取长补短，进一步促进合作的深入。中方优势还体现于其强大的淋巴瘤治疗团队及丰富的病例标本资源，而瑞方的优势体现在利用新一代高通量测序技术筛选、鉴定B细胞淋巴瘤靶向治疗的靶标，并取得一定成果。本项目将支持中瑞双方合作交流，拟每半年共同举办一次双方参加的国际会议，包括举办淋巴瘤夏季学习班（每次规模20-30 人）；成立淋巴瘤基因组研究国际工作组，每年举办一次广州淋巴瘤国际高峰论坛（每次规模100-300 人），推动在研基金项目的顺利开展以及国内和国际淋巴瘤多学科的交流和合作。

This project is based on the support of a project of National Nature Science Foundation of China: "To regulate the efficacy BTK inhibitor ibrutinib on lymphoma based on the non-classical BAFF/MyD88/NIK NF- NF kappa B signaling pathway and to explore the mechanism” (Project Investigator: Li Zhiming). Both Dr. QIANG PAN HAMMARSTR and Dr. Li Zhiming graduated from Sun Yat-sen University of Medical Sciences. In additional, Dr. Pan currently is a visiting professor in the Sun Yat-sen University Cancer Center. The same educational background could benefit future cooperation and communicate. Different work experience could drive the both sides to learn from each other, and promote the deepening of the cooperation. The advantage of Chinese side is the very goodl lymphoma treatment team and abundant lymphoma sample resources. On the other hand, the advantage of Sweden is that they have the new generation of high-throughput sequencing technology to screen and identify new targets of B cell lymphoma. The project will support the cooperation and exchange between both sides to organize an international meeting at a scale of about 30 people) and to establish lymphoma genome research international working group and to hold an annual lymphoma International Summit Forum (with a scale of 100-300 people), in order to help to carry out the project smoothly and strength the exchanges and cooperation between the domestic and international Lymphoma translational research.